Natriuretic peptides and cGMP signaling control of energy homeostasis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 3, 2013, Pages

  Moro, Cedric ^a   Lafontan, Max ^b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Fat oxidation; Lipolysis; Obesity; Skeletal muscle; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NATRIURETIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHODIESTERASE V; RETINOL BINDING PROTEIN 4; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1;

BLOOD PRESSURE REGULATION; BROWN ADIPOSE TISSUE; CELL METABOLISM; CYTOKINE PRODUCTION; ENERGY EXPENDITURE; ENERGY METABOLISM; GENETIC POLYMORPHISM; HORMONE RELEASE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; LIVER; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PANCREAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; THERMOGENESIS; WHITE ADIPOSE TISSUE;

ADIPOKINES; ADIPOSE TISSUE; ADIPOSE TISSUE, BROWN; ANIMALS; CYCLIC GMP; CYTOKINES; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; MUSCLE, SKELETAL; NATRIURETIC PEPTIDES; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84873319246     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00704.2012     Document Type: Review

References (97)

1. Agustsson T, Ryden M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, Isaksson B, Permert J, Arner P. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 67: 5531-5537, 2007.
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
3. Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kita-kaze M. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 68: 95-100, 2004.
4. Aversa A, Caprio M, Antelmi A, Armani A, Brama M, Greco EA, Francomano D, Calanchini M, Spera G, Di Luigi L, Rosano GM, Lenzi A, Migliaccio S, Fabbri A. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med 8: 696-704, 2011.
5. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56: 1025-1033, 2007.
6. Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 151: 5218-5225, 2010.
7. Bilzer M, Jaeschke H, Vollmar AM, Paumgartner G, Gerbes AL. Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. Am J Physiol Gastrointest Liver Physiol 276: G1137- G1144, 1999.
8. Birkenfeld AL, Adams F, Schroeder C, Engeli S, Jordan J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension 57: e4-e5, 2011.
9. Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, Jordan J. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One 7: e43238, 2012.
10. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, Jordan J. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90: 3622-3628, 2005.
11. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Tank J, Diedrich A, Schroeder C, Franke G, Berlan M, Luft FC, Lafontan M, Jordan J. Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. J Clin Endocrinol Metab 91: 5069-5075, 2006.
12. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, Berlan M, Marques MA, Sweep FC, Luft FC, Lafontan M, Jordan J. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 57: 3199-3204, 2008.
13. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 122: 1022-1036, 2012.
14. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8: 347-354, 2005.
15. Broderick TL, Jankowski M, Wang D, Danalache BA, Parrott CR, Gutkowska J. Downregulation in GATA4 and downstream structural and contractile genes in the db/db mouse heart. ISRN Endocrinol 2012: 736860, 2012.
16. Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, Floering LM, Spiegelman BM, Collins S. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol 24: 3057-3067, 2004.
17. Cao W, Medvedev AV, Daniel KW, Collins S. beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. J Biol Chem 276: 27077-27082, 2001.
18. Civitarese AE, Carling S, Heilbronn LK, Hulver MH, Ukropcova B, Deutsch WA, Smith SR, Ravussin E. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 4: e76, 2007.
19. Clerico A, Fontana M, Vittorini S, Emdin M. The search for a patho-physiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. Clin Chim Acta 405: 1-7, 2009.
20. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 301: H12-H20, 2011.
21. Clerico A, Passino C, Emdin M. When gonads talk to the heart sex hormones and cardiac endocrine function. J Am Coll Cardiol 58: 627-628, 2011.
22. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA.Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112: 2163-2168, 2005.
23. a.de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28: 89-94, 1981.
24. De Vito P, Incerpi S, Pedersen JZ, Luly P. Atrial natriuretic peptide and oxidative stress. Peptides 31: 1412-1419, 2010.
25. Deshmukh AS, Long YC, de Castro Barbosa T, Karlsson HK, Glund S, Zavadoski WJ, Gibbs EM, Koistinen HA, Wallberg-Henriksson H, Zierath JR. Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)alpha1-specific activity and glucose transport in human skeletal muscle. Diabetologia 53: 1142-1150, 2010.
26. Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I, de Glisezinski I, Lieske S, Reinke J, Beckmann B, Langin D, Jordan J, Moro C. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Investig 122: 4675-4679, 2012.
27. Fain JN, Kanu A, Bahouth SW, Cowan GS, Lloyd Hiler M. Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem Pharmacol 65: 1883-1888, 2003.
28. Galitzky J, Sengenes C, Thalamas C, Marques MA, Senard JM, Lafontan M, Berlan M. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 42: 536-544, 2001.
29. Gardner DG. Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab 14: 411-416, 2003.
30. Horowitz JF. Fatty acid mobilization from adipose tissue during exercise. Trends Endocrinol Metab 14: 386-392, 2003.
31. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 116: 1784-1792, 2006.
32. Kalra PR, Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125-132, 2002.
33. Kiemer AK, Baron A, Gerbes AL, Bilzer M, Vollmar AM. The atrial natriuretic peptide as a regulator of Kupffer cell functions. Shock 17: 365-371, 2002.
34. Kiemer AK, Gerwig T, Gerbes AL, Meissner H, Bilzer M, Vollmar AM. Kupffer-cell specific induction of heme oxygenase 1 (hsp32) by the atrial natriuretic peptide-role of cGMP. J Hepatol 38: 490-498, 2003.
35. Kiemer AK, Hartung T, Vollmar AM. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macro-phages. J Immunol 165: 175-181, 2000.
36. Konig D, Schumacher YO, Heinrich L, Schmid A, Berg A, Dickhuth HH. Myocardial stress after competitive exercise in professional road cyclists. Med Sci Sports Exerc 35: 1679-1683, 2003.
37. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, Weitzberg E. Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab 13: 149-159, 2011.
38. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 81: 45-50, 1998.
39. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258, 2010.
40. Lutz SZ, Hennige AM, Feil S, Peter A, Gerling A, Machann J, Krober SM, Rath M, Schurmann A, Weigert C, Haring HU, Feil R. Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes 60: 1566-1576, 2011.
41. Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, Morgenthaler NG, Nilsson P, Newton-Cheh C, Wang TJ, Melander O. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab 97: 638-645, 2012.
42. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96: 7403-7408, 1999.
43. McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 7: 93-99, 2010.
44. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43: 1590-1595, 2004.
45. Meirhaeghe A, Sandhu MS, McCarthy MI, de Groote P, Cottel D, Arveiler D, Ferrieres J, Groves CJ, Hattersley AT, Hitman GA, Walker M, Wareham NJ, Amouyel P. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 16: 1343-1350, 2007.
46. Mitsuishi M, Miyashita K, Itoh H. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun 367: 840-845, 2008.
47. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, Nakao K. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880-2892, 2009.
48. Monti LD, Lucotti PC, Setola E, Rossodivita A, Pala MG, Galluccio E, LaCanna G, Castiglioni A, Cannoletta M, Meloni C, Zavaroni I, Bosi E, Alfieri O, Piatti PM. Effects of chronic elevation of atrial natriuretic peptide and free fatty acid levels in the induction of type 2 diabetes mellitus and insulin resistance in patients with mitral valve disease. Nutr Metab Cardiovasc Dis 22: 58-65, 2012.
49. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55, Suppl 2: S9-S15, 2006.
50. Moro C, Crampes F, Sengenes C, De Glisezinski I, Galitzky J, Thalamas C, Lafontan M, Berlan M. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J 18: 908-910, 2004.
51. Moro C, Galgani JE, Luu L, Pasarica M, Mairal A, Bajpeyi S, Schmitz G, Langin D, Liebisch G, Smith SR. Influence of gender, obesity, and muscle lipase activity on intramyocellular lipids in sedentary individuals. J Clin Endocrinol Metab 94: 3440-3447, 2009.
52. Moro C, Galitzky J, Sengenes C, Crampes F, Lafontan M, Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther 308: 984-992, 2004.
53. Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzky J. Phospho-diesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. Br J Pharmacol 152: 1102-1110, 2007.
54. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzky J, Arner P, Langin D. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50: 1038-1047, 2007.
55. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endo-crinol Metab 94: 2579-2586, 2009.
56. Moro C, Pillard F, de Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am J Physiol Regul Integr Comp Physiol 293: R612- R617, 2007.
57. Moro C, Pillard F, de Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Sex differences in lipolysis-regulating mechanisms in overweight subjects: effect of exercise intensity. Obesity (Silver Spring) 15: 2245-2255, 2007.
58. Moro C, Pillard F, De Glisezinski I, Harant I, Riviere D, Stich V, Lafontan M, Crampes F, Berlan M. Training enhances ANP lipid-mobilizing action in adipose tissue of overweight men. Med Sci Sports Exerc 37: 1126-1132, 2005.
59. Moro C, Polak J, Richterova B, Sengenes C, Pelikanova T, Galitzky J, Stich V, Lafontan M, Berlan M. Differential regulation of atrial natri-uretic peptide- and adrenergic receptor-dependent lipolytic pathways in human adipose tissue. Metabolism 54: 122-131, 2005.
60. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T, Shimomura I. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 392: 100-105, 2010.
61. Niessner A, Ziegler S, Slany J, Billensteiner E, Woloszczuk W, Geyer G. Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adreno-cortical steroids? Eur J Endocrinol 149: 555-559, 2003.
62. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28: 22-30, 1996.
63. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896-899, 2003.
64. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, Clementi E. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA 101: 16507-16512, 2004.
65. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310: 314-317, 2005.
66. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dick-stein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMur-ray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365: 32-43, 2011.
67. Ouellet V, Labbe SM, Blondin DP, Phoenix S, Guerin B, Haman F, Turcotte EE, Richard D, Carpentier AC. Brown adipose tissue oxida-tive metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest 122: 545-552, 2012.
68. Pandey KN. Guanylyl cyclase/atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. Can J Physiol Pharmacol 89: 557-573, 2011.
69. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC, Bluher M, Pfeiffer AF, Rudovich N. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab 97: E731-E739, 2012.
70. Polak J, Kotrc M, Wedellova Z, Jabor A, Malek I, Kautzner J, Kazdova L, Melenovsky V. Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol 58: 1119-1125, 2011.
71. Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal 23: 1921-1926, 2011.
72. Ravussin E, Galgani JE. The implication of brown adipose tissue for humans. Annu Rev Nutr 31: 33-47, 2011.
73. Ropero AB, Soriano S, Tuduri E, Marroqui L, Tellez N, Gassner B, Juan-Pico P, Montanya E, Quesada I, Kuhn M, Nadal A. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology 151: 3665-3674, 2010.
74. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375: 1255-1266, 2010.
75. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PloS One 5: e10100, 2010.
76. Sarzani R, Dessi-Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 17: 1301-1305, 1999.
77. Sarzani R, Paci VM, Zingaretti CM, Pierleoni C, Cinti S, Cola G, Rappelli A, Dessi-Fulgheri P. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J Hypertens 13: 1241-1246, 1995.
78. Sarzani R, Strazzullo P, Salvi F, Iacone R, Pietrucci F, Siani A, Barba G, Gerardi MC, Dessi-Fulgheri P, Rappelli A. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 12: 351-356, 2004.
79. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14: 1345-1351, 2000.
80. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, Galitzky J. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278: 48617-48626, 2003.
81. Sengenes C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumie A, Lafontan M, Galitzky J. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 283: R257-R265, 2002.
82. Souza SC, Chau MD, Yang Q, Gauthier MS, Clairmont KB, Wu Z, Gromada J, Dole WP. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. Biochem Biophys Res Commun 410: 398-403, 2011.
83. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 69: 283-290, 2005.
84. Topol EJ. The lost decade of nesiritide. N Engl J Med 365: 81-82, 2011.
85. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53: 2070-2077, 2009.
86. Uehlinger DE, Weidmann P, Gnadinger MP, Hasler L, Bachmann C, Shaw S, Hellmuller B, Lang RE. Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol 8: 1122-1129, 1986.
87. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6: 261-268, 2004.
88. Vila G, Grimm G, Resl M, Heinisch B, Einwallner E, Esterbauer H, Dieplinger B, Mueller T, Luger A, Clodi M. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 61: 2592-2596, 2012.
89. Vink S, Jin AH, Poth KJ, Head GA, Alewood PF. Natriuretic peptide drug leads from snake venom. Toxicon 59: 434-445, 2012.
90. Vogel MW, Chen HH. Novel natriuretic peptides: new compounds and new approaches. Curr Heart Fail Rep 8: 22-27, 2011.
91. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73: 298-309, 2007.
92. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115: 1345-1353, 2007.
93. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600, 2004.
94. Wang YH, Donaldson L, Gehring C, Irving HR. Plant natriuretic peptides: control of synthesis and systemic effects. Plant Signal Behav 6: 1606-1608, 2011.
95. Wu HT, Chang CK, Cheng KC, Chang CH, Yeh CH, Cheng JT. Increase of plasma insulin by racecadotril, an inhibitor of enkephalinase, in Wistar rats. Horm Metab Res 42: 261-267, 2010.
96. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus. Circ J 73: 2264-2269, 2009.
97. Yu J, Yu HC, Kim KA, Kwon KB, Park JW, Kim SZ, Kim SH, Park BH. Differences in the amount of lipolysis induced by atrial natriuretic peptide in small and large adipocytes. J Pept Sci 14: 972-977, 2008.